2 results
Approved WMORecruitment started
The objective of this study is to establish the clinical performance of VENTANA PD-L1 (SP263) CDx Assay as a companion diagnostic (CDx) for the identification of patients with NSCLC who may benefit from treatment with [redacted]. …
Approved WMOPending
The main objective of this study is to validate the specificity of 100% for peripheral thrombocytopenia of an IPF cut-off value of 13% in our patient population and workflow. In addition, if the specificity of 100% cannot be validated at a cut-off…